Mostrar el registro sencillo del ítem
Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors
dc.contributor.author | Costas-Lago M.C. | |
dc.contributor.author | Besada P. | |
dc.contributor.author | Rodríguez-Enríquez F. | |
dc.contributor.author | Viña D. | |
dc.contributor.author | Vilar S. | |
dc.contributor.author | Uriarte E. | |
dc.contributor.author | Borges F. | |
dc.contributor.author | Terán C. | |
dc.date.accessioned | 2020-09-02T22:15:33Z | |
dc.date.available | 2020-09-02T22:15:33Z | |
dc.date.issued | 2017 | |
dc.identifier | 10.1016/j.ejmech.2017.07.045 | |
dc.identifier.citation | 139, , 1-11 | |
dc.identifier.issn | 02235234 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/4106 | |
dc.description | Compounds of hybrid structure pyridazine-coumarin were discovered as potent, selective and reversible inhibitors of monoamine oxidase B (MAO-B). These compounds were synthesized in good yield following a multistep approach based on Knoevenagel reaction and using as key intermediate pyridazinone 16, which was obtained from maleic anhydride and furan. Compounds 9b and 9d are the most active compounds of these series, with IC50 values in the sub-micromolar range, and lack of cytotoxic effects. Theoretical calculation of ADME properties also suggested a good pharmacokinetic profile for both compounds. Docking simulations provided insights into enzyme inhibitor interactions and allowed us to rationalize the observed structure-activity relationships (SARs). © 2017 Elsevier Masson SAS | |
dc.language.iso | en | |
dc.publisher | Elsevier Masson SAS | |
dc.subject | ADME | |
dc.subject | Coumarin | |
dc.subject | MAO-B | |
dc.subject | Molecular modeling | |
dc.subject | Neurodegenerative disorders | |
dc.subject | Pyridazine | |
dc.subject | 3 (6 bromopyridazin 3 yl) 6 methoxycoumarin | |
dc.subject | 3 (6 bromopyridazin 3 yl) 6 methylcoumarin | |
dc.subject | 3 (6 bromopyridazin 3 yl) 7 methoxycoumarin | |
dc.subject | 3 (6 bromopyridazin 3 yl) 7 methylcoumarin | |
dc.subject | 3 (6 bromopyridazin 3 yl) 8 methoxycoumarin | |
dc.subject | 3 (6 bromopyridazin 3 yl) 8 methylcoumarin | |
dc.subject | 3 (6 chloropyridazin 3 yl) 6 methoxycoumarin | |
dc.subject | 3 (6 chloropyridazin 3 yl) 6 methylcoumarin | |
dc.subject | 3 (6 chloropyridazin 3 yl) 7 methoxycoumarin | |
dc.subject | 3 (6 chloropyridazin 3 yl) 7 methylcoumarin | |
dc.subject | 3 (6 chloropyridazin 3 yl) 8 methoxycoumarin | |
dc.subject | 3 (6 chloropyridazin 3 yl) 8 methylcoumarin | |
dc.subject | 3 (6 methoxypyridazin 3 yl) 6 methylcoumarin | |
dc.subject | 3 (6 methoxypyridazin 3 yl) 7 methylcoumarin | |
dc.subject | 3 (6 methoxypyridazin 3 yl) 8 methylcoumarin | |
dc.subject | 6 methoxy 3 (6 methoxypyridazin 3 yl)coumarin | |
dc.subject | 6 methoxy 3 (6 oxo 1,6 dihydropyridazin 3 yl)coumarin | |
dc.subject | 7 methoxy 3 (6 methoxypyridazin 3 yl)coumarin | |
dc.subject | 7 methoxy 3 (6 oxo 1,6 dihydropyridazin 3 yl)coumarin | |
dc.subject | 7 methyl 3 (6 oxo 1,6 dihydropyridazin 3 yl)coumarin | |
dc.subject | 8 methoxy 3 (6 methoxypyridazin 3 yl)coumarin | |
dc.subject | 8 methoxy 3 (6 oxo 1,6 dihydropyridazin 3 yl)coumarin | |
dc.subject | 8 methyl 3 (6 oxo 1,6 dihydropyridazin 3 yl)coumarin | |
dc.subject | coumarin derivative | |
dc.subject | ethyl 2 (6 oxo 1,6 dihydropyridazin 3 yl)acetate | |
dc.subject | furan | |
dc.subject | maleic anhydride | |
dc.subject | monoamine oxidase B inhibitor | |
dc.subject | pyridazine | |
dc.subject | unclassified drug | |
dc.subject | amine oxidase (flavin containing) | |
dc.subject | coumarin derivative | |
dc.subject | monoamine oxidase inhibitor | |
dc.subject | pyridazine | |
dc.subject | pyridazine derivative | |
dc.subject | Article | |
dc.subject | controlled study | |
dc.subject | cytotoxicity | |
dc.subject | drug potency | |
dc.subject | drug selectivity | |
dc.subject | drug synthesis | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | hybrid | |
dc.subject | IC50 | |
dc.subject | Knoevenagel condensation | |
dc.subject | molecular docking | |
dc.subject | structure activity relation | |
dc.subject | theoretical model | |
dc.subject | chemical structure | |
dc.subject | chemistry | |
dc.subject | dose response | |
dc.subject | metabolism | |
dc.subject | structure activity relation | |
dc.subject | synthesis | |
dc.subject | Coumarins | |
dc.subject | Dose-Response Relationship, Drug | |
dc.subject | Humans | |
dc.subject | Molecular Docking Simulation | |
dc.subject | Molecular Structure | |
dc.subject | Monoamine Oxidase | |
dc.subject | Monoamine Oxidase Inhibitors | |
dc.subject | Pyridazines | |
dc.subject | Structure-Activity Relationship | |
dc.title | Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors | |
dc.type | Article |